Cord Blood America Reduces Initial Storage Fee to $495 With Launch of 'Afford-A-Cord' Program

Wednesday, May 26, 2010 General News
Email Print This Page Comment bookmark
Font : A-A+

LAS VEGAS, May 26 Cord Blood America, Inc. ( (OTC Bulletin Board: CBAI), announced today its stem cell processing and storage subsidiary, CorCell, is launching "Afford-A-Cord," which reduces the initial cost of storing umbilical cord blood stem cells from $2075 to $495 plus medical courier service. The Afford-A-Cord program will be offered as an additional payment option to CorCell's long standing traditional payment programs.

"We have for years heard that the biggest barrier to utilizing our service, and all others in the sector, is the upfront cost, which often comes at a time, with the birth of a baby, that a family can least afford it. Those pressures coupled with an uncertain economic environment make the decision to store much more difficult. I'm pleased to announce that Cord Blood America's financial position has improved to the extent that we can lower this cost and serve those with limited cash reserves," said Matthew Schissler, Cord Blood America co-founder and CEO.

"We believe that providing a variety of flexible payment plans is paramount to obtaining a greater market share in the industry. No other company offers such a low entry point, one that will allow a greater number of families to store their child's stem cells. "We know that having a baby involves a lot of expenses. That is why CorCell is minimizing the upfront fee and providing a financial vehicle that will fit most every budget and allow more families to take advantage of the potential medical advances from the use of stem cells. The monthly fee after birth is $29 for 18 years of storage, which is paid directly with electronic funds transfer."

Mr. Schissler said, "We have been working on the legal and accounting aspects of this program for many months. It is scheduled to launch on or before July 1, 2010 and we are very pleased to bring this program to American families." Cord Blood America's CEO said he is confident the program will add to the Company's revenue stream. "With the addition in the second quarter of 2010 of revenues from our company in Germany, we are expecting the best quarter for cord blood subsidiary sales in the Company's history."

"I need to stress that CorCell's current payment plans are still, and will continue to be, in full effect. The Afford-A-Cord program is an additional payment option designed specifically to attract consumers whose primary hurdle to cord blood stem cell storage has been the initial cost," Mr. Schissler said.

Cord Blood America is the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally.

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at For investor information, visit

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect,'' "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

CONTACT: Paul Knopick E & E Communications 949/707-5365

SOURCE Cord Blood America, Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store